The percentage of pre-NAC samples with a DCIS component was higher for HER2-positive BC (29.5%) than for luminal BC (21.3%) or TNBC (9.5%) (Figure 1). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.